| DiPersio, John F |
GENESIS, NCT03246529 / 2018-001715-79: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) |
|
|
| Active, not recruiting | 3 | 180 | Europe, US | BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF | BioLineRx, Ltd. | Multiple Myeloma | 12/20 | 09/29 | | |
NCT06483100: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance |
|
|
| Recruiting | 2 | 65 | US | Elrantamab, clonoSEQ | Washington University School of Medicine, National Comprehensive Cancer Network, Pfizer, Rapid Novor | Multiple Myeloma | 12/31 | 12/31 | | |
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation |
|
|
| Recruiting | 2 | 60 | US | Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis | Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc. | Acute Myeloid Leukemia | 07/26 | 07/26 | | |
NCT04582864: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) |
|
|
| Terminated | 2 | 11 | US | Flotetuzumab, MGD006, Donor lymphocyte infusion, DLI | Washington University School of Medicine, MacroGenics, National Cancer Institute (NCI) | Relapsed Acute Myeloid Leukemia | 03/24 | 07/24 | | |
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML |
|
|
| Withdrawn | 2 | 48 | NA | Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis | Washington University School of Medicine | Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | 09/26 | 07/28 | | |
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant |
|
|
| Withdrawn | 2 | 35 | NA | Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron | Washington University School of Medicine, Karyopharm Therapeutics Inc | Multiple Myeloma, Myeloma-Associated Amyloidosis | 01/27 | 01/27 | | |
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas |
|
|
| Active, not recruiting | 2 | 17 | US | Duvelisib, Copiktra, Peripheral blood draw | Washington University School of Medicine, SecuraBio | T-Cell Lymphoma | 07/26 | 07/26 | | |
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance |
|
|
| Active, not recruiting | 2 | 107 | US | Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq | Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology | Acute Myeloid Leukemia | 07/29 | 07/29 | | |
CEDAR, NCT04819841: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease |
|
|
| Recruiting | 1/2 | 15 | US | nula-cel Drug Product | Kamau Therapeutics | Sickle Cell Disease | 07/26 | 07/27 | | |
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS |
|
|
| Recruiting | 1/2 | 24 | Canada, US | VOR33, Mylotarg, gemtuzumab ozogamicin | Vor Biopharma | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 02/25 | 01/27 | | |
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant |
|
|
| Recruiting | 1/2 | 24 | US | VCAR33 | Vor Biopharma | Leukemia, Myeloid, Acute | 12/24 | 11/26 | | |
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 53 | US | GDX012, Chemotherapy Agents | Takeda | Leukemia | 04/26 | 06/27 | | |
NCT03687957: rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide |
|
|
| Active, not recruiting | 1/2 | 42 | US | rhIL-7-hyFc, Placebo, Temozolomide, TMZ, Radiation therapy, RT, Blood sample | Washington University School of Medicine, NeoImmuneTech, The Foundation for Barnes-Jewish Hospital | Glioma | 02/25 | 01/32 | | |
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease |
|
|
| Terminated | 1 | 1 | US | Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone | Washington University School of Medicine, Sanofi | Multiple Myeloma | 12/22 | 01/24 | | |
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients |
|
|
| Terminated | 1 | 4 | US | ApoGraft | Washington University School of Medicine, Cellect Biotechnology | Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant | 12/22 | 12/22 | | |
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma |
|
|
| Terminated | 1 | 15 | US | Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol | Washington University School of Medicine, Sanofi | Multiple Myeloma | 03/23 | 03/24 | | |
|
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) |
|
|
| Recruiting | 1 | 10 | US | Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis | Washington University School of Medicine, BioLineRx, Ltd., Biogen | Sickle Cell Disease | 12/25 | 12/25 | | |
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Completed | 1 | 55 | US | Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile | Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI) | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease | 04/24 | 05/24 | | |
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias |
|
|
| Recruiting | 1 | 76 | US | SNDX-5613, Chemotherapy Regimen, HiDAC | Syndax Pharmaceuticals | Acute Myeloid Leukemias | 02/27 | 02/27 | | |
NCT06185751: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma |
|
|
| Recruiting | 1 | 25 | US | WS-CART-CS1, Lymphodepleting chemotherapy | Washington University School of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research | Multiple Myeloma | 08/29 | 08/40 | | |
NCT06547112: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization |
|
|
| Recruiting | 1 | 20 | US | Motixafortide, BL-8040, G-CSF | Washington University School of Medicine, BioLineRx, Ltd. | Multiple Myeloma | 01/26 | 01/26 | | |
NCT06523699: Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant |
|
|
| Not yet recruiting | 1 | 30 | US | Recombinant glycosylated human interleukin-7, CYT107, r-hIL-7, Melphalan, Autologous hematopoietic cell transplant, AHCT | Washington University School of Medicine, Revimmune | Multiple Myeloma | 01/29 | 01/29 | | |
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms |
|
|
| Active, not recruiting | 1 | 63 | US | NC525 | NextCure, Inc. | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome | 05/25 | 05/25 | | |
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy |
|
|
| Recruiting | 1 | 43 | US | Duvelisib | Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI) | Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia | 12/25 | 05/30 | | |
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma |
|
|
| Recruiting | 1 | 15 | US | Mosunetuzumab, RO7030816, BTCT4465A | Washington University School of Medicine, Genentech, Inc. | B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3 | 07/27 | 06/29 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies |
|
|
| Recruiting | 1 | 54 | US | WU-CART-007 | Washington University School of Medicine, Wugen, Inc. | T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma | 04/26 | 04/26 | | |
| Available | N/A | | US | Revumenib, SNDX-5613 | Syndax Pharmaceuticals | Relapsed/Refractory Acute Leukemia | | | | |
NCT04614987: Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy |
|
|
| Terminated | N/A | 17 | US | | Washington University School of Medicine, McDonnell Center, Paula and Roger Riney Blood Cancer Research | Neurotoxicity | 09/23 | 09/23 | | |
NCT02611180: Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease |
|
|
| Recruiting | N/A | 50 | US | Skin punch biopsy, Peripheral blood draw | Washington University School of Medicine | Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD | 04/25 | 04/25 | | |
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration |
|
|
| Recruiting | N/A | 165 | US | Peripheral blood draw, Bone marrow aspirate, Buccal swab | Washington University School of Medicine, Notable Labs | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 01/25 | 01/25 | | |
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33 |
|
|
| Recruiting | N/A | 36 | Canada, US | VOR33 | Vor Biopharma | Leukemia, Myeloid, Acute | 01/40 | 01/40 | | |
| Monahan, Ryan |
| No trials found |
